Navigation Links
Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
Date:7/1/2008

KENILWORTH, N.J., July 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the successful closing of its previously announced transaction with Virbac, S.A. to divest animal health products from selected franchises. These divestments were requested by the European Commission as part of its October 2007 clearance of the acquisition of Organon BioSciences N.V.

In Europe, Virbac acquired products from the endocrine, mastitis and sulphonamide franchises of Intervet/Schering-Plough Animal Health. The agreement does not affect the marketing of these products in other global markets. In a second agreement with Virbac that has also closed successfully, Virbac acquired Prosolvin, a product from the fertility range, for worldwide use. That acquisition also satisfied a request by the South African Competition Commission in connection with Schering-Plough's 2007 acquisition of Organon BioSciences N.V. Virbac has acquired these assets for an aggregate euro 28 million in cash.

By separate agreement announced in April, products from Intervet/Schering-Plough Animal Health's parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory, companion animal/insulin and companion animal/euthanasia, and rabies vaccine franchises will be acquired by a subsidiary of Pfizer. The closing of that transaction is expected to take place later this year following receipt of necessary regulatory approvals.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the worl
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
2. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
3. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
4. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
5. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
6. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
7. Schering-Plough CEO Buys $2 Million in Common Shares
8. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
9. Schering-Plough Reports Financial Results for First Quarter of 2008
10. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
11. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/20/2014)... 20, 2014 Earle Martin ... announced today that Ellen Teplitzky, an experienced attorney ... the pharmaceutical industry, has joined the firm as ... legal services practice. NDA Partners provides legal ... and testimony, to top law firms and their ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... to the biotech community to have a major research facility ... the Wisconsin Life Sciences and Venture Conference program ... conference will be held November 16 and 17. , ,The ... companies, 11 from Wisconsin, will strut their stuff in front ...
... to those risk-addicted Californians: Saddled with a debt running into ... their credit cards and pinch pennies. They borrow even more ... happened last week when California voters overwhelmingly approved Proposition 71, ... in bonds to pay for human embryonic stem cell research. ...
... Wisconsin-Madison Board of Regents has approved construction of a new ... and Clinics and the Waisman Center . The ... from the State Building Commission on November 17. , ,The ... an imaging center and animal quarters. The facility is designed ...
Cached Biology Technology:Life-sciences conference to feature novel research with clinical potential 2California stem cell initiative should wake up Washington and Madison 2California stem cell initiative should wake up Washington and Madison 3
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... seen amongst individual species within the animal kingdom evolved ... effectively serve as medical research models because humans and ... key to morphological and behavioral complexity, a growing body ... expression by a family of DNA-binding proteins called "transcription ...
... AUSTIN, Texas Researchers at The University of Texas at ... in the folic acid metabolic pathway leads to neural tube ... known for several decades that folic acid supplementation dramatically reduces ... and anencephaly, which are among the most common birth defects. ...
... press release is available in German . ... at the Max Planck Institute for Developmental Biology in ... to identify neuronal correlates of behaviour by comparing maps ... different behaviour. They compared the pharyngeal nervous systems of ...
Cached Biology News:New key to organism complexity identified 2New key to organism complexity identified 3New key to organism complexity identified 4Lack of key enzyme in the metabolism of folic acid leads to birth defects 2The neurobiological consequence of predating or grazing 2The neurobiological consequence of predating or grazing 3
X-gal,1g...
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
... Peptide-Protein Conjugation, ... Bridges, Complex Peptides/Peptidomimetics, Special ... Phosphorylated/Biotinylated Structures, Peptide labeling AMC, ... -99%, fitting your needs, Chromogenic/Flurogenic ...
... Osteocalcin EIA Kit is an in ... quantitative determination of human Gla-OC in ... supernatants, and other biological fluids. ... only. It is not for use ...
Biology Products: